Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in ...
Rat LD50 values were taken from the Registry of Toxic Effects of Chemical Substances (RTECS) database [55] and cytotoxicity values were taken from the public National Cancer Institute (NCI) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback